GSK — GSK plc

GSK Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Sales: Increased by 7% to over GBP 32 billion, driven by Specialty Medicines (+17%).
• Core Operating Profit: Grew by 11%.
• Earnings Per Share (EPS): Up 12%.
• Cash Generation: Strong at GBP 8.9 billion, allowing for a dividend increase from 64p to 66p.
• Research & Development (R&D): 5 FDA approvals and 7 new pivotal trial starts in 2025.

2. Strategic Updates and Business Highlights

• Focus Areas for 2026:
  • Maximize launch products like Blenrep and Exdensur.
  • Accelerate late-stage assets in oncology and respiratory diseases.
  • Enhance business development efforts, including the recent acquisition of Ozekibart for food allergies.
• Specialty Medicines: Continued strong performance, with a forecast of low double-digit growth for 2026.
• Vaccines: Sales of GBP 9.2 billion, up 2%, with Shingrix showing growth in Europe and international markets.
• HIV Portfolio: Long-acting injectables driving growth, with Cabenuva sales up 42%. Upcoming Q6M treatment expected to significantly expand market share.

3. Forward Guidance and Outlook

• 2026 Guidance:
  • Sales growth expected at 3% to 5%.
  • Core operating profit and EPS projected to grow by 7% to 9%.
  • Dividend forecasted at 70p, a 6% increase.
• Product Area Expectations:
  • Specialty Medicines to lead growth.
  • Vaccines and General Medicines expected to see low single-digit declines or stabilize.

4. Bad News, Challenges, or Points of Concern

• Declining Metrics: Sales for ZEJULA decreased due to FDA labeling restrictions.
• Vaccines: Anticipated low single-digit decline in Shingrix sales in the U.S. due to slowing immunization rates.
• R&D Staff Reduction: Approximately 350 positions cut in the U.S. and U.K., raising concerns about resource allocation and focus.
• Currency Headwinds: Expected negative impact on sales (-3%) and operating profit (-6%) if exchange rates remain stable.

5. Notable Q&A Insights

• COPD and Asthma Strategy: GSK is focusing on a diverse range of treatments for COPD, with a clear strategy to target different patient populations and avoid overlap in product positioning.
• HIV Market Dynamics: Anticipated decline in sales due to loss of exclusivity for dolutegravir, but confidence in long-acting treatments to drive future growth.
• Blenrep Launch: Initial uptake is slower due to the need for coordination with eye care professionals, but early feedback is positive. The launch is expected to ramp up gradually.
• Financials of Q6M Treatment: Plans to include Q6M in long-term forecasts once Phase II trials commence, with expectations of significant market capture.

Overall, GSK reported a strong performance in 2025 with a positive outlook for 2026, despite facing some challenges in specific product areas and market dynamics.